A5085750369- Advanced Breast Cancer Therapies
- Meta-analysis and systematic reviews
- Statistical Methods in Clinical Trials
- PI3K/AKT/mTOR signaling in cancer
- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Statistical Methods and Bayesian Inference
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Alzheimer's disease research and treatments
- Brain Metastases and Treatment
- Neuroblastoma Research and Treatments
- Oral microbiology and periodontitis research
- Reliability and Agreement in Measurement
- Oral Health Pathology and Treatment
- Breast Cancer Treatment Studies
- Renal cell carcinoma treatment
- Cholinesterase and Neurodegenerative Diseases
- Glioma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Sepsis Diagnosis and Treatment
- Advanced Biosensing Techniques and Applications
- Oral and gingival health research
- Advanced Causal Inference Techniques
- Cancer Mechanisms and Therapy
Third Hospital of Changsha
2025
WuXi AppTec (China)
2025
Guiyang Medical University
2024
Affiliated Hospital of Guizhou Medical University
2024
University of Minnesota
2017-2021
University of North Carolina at Chapel Hill
2017
University of Pennsylvania
2017
PI3K/AKT pathway alterations are frequent in hormone receptor-positive (HR+) breast cancers. IPATunity130 Cohort B investigated ipatasertib-paclitaxel PI3K pathway-mutant HR+ unresectable locally advanced/metastatic cancer (aBC).Cohort of the randomized, double-blind, placebo-controlled, phase 3 trial enrolled patients with HER2-negative PIK3CA/AKT1/PTEN-altered measurable aBC who were considered inappropriate for endocrine-based therapy (demonstrated insensitivity to endocrine or visceral...
Abstract Background: The risk of HCC recurrence after liver resection or ablation with curative intent is 70-80% within 5 years, indicating an unmet need for effective adjuvant therapies. Atezolizumab (atezo) bevacizumab (bev) the standard care unresectable based on IMbrave150 study, which demonstrated statistically significant and clinically meaningful improvements in overall survival (OS), progression-free survival, objective response rate versus sorafenib (Finn NEJM 2020, Cheng J Hepatol...
Background: Crenezumab is a fully humanized, monoclonal anti-amyloid-β immunoglobulin G4 antibody. Objective: This Phase Ib study (NCT02353598) evaluated the safety, tolerability, and pharmacokinetics of crenezumabat doses ≤120 mg/kg administered intravenously every 4 weeks (q4w). Immunogenicity exploratory biomarkers were also evaluated. Methods: In this multicenter, double-blind study, participants (aged 50–90 years) with mild-to-moderate Alzheimer’s disease (AD) amyloid-positive positron...
Sepsis continues to be a major problem for hospitalized patients. Opioids are widely used medications pain management despite recent evidence revealing their adverse effects. The present study evaluates survival differences between opioid-treated patients and non-opioid-treated with diagnosis of sepsis. Clinical data was extracted from the University Minnesota's Data Repository, which includes Electronic Health Records (EHRs) seen at 8 hospitals. Among 5,994 diagnosed sepsis, 4,540 1,454...
Abstract Background: In the randomized phase II LOTUS trial [Kim, Lancet Oncol 2017], adding IPAT to PAC improved progression-free survival (PFS), with a more pronounced effect in patients PIK3CA/AKT1/PTEN-altered tumors. This provided rationale for biomarker-selected IPATunity130 III trial. Here we report primary results from Cohort A aTNBC. Patients and methods: of this pivotal (NCT03337724), eligible had PIK3CA- and/or AKT1- PTEN-altered measurable aTNBC, ECOG performance status 0/1, were...
4002 Background: In IMbrave050, adjuvant atezo + bev demonstrated a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS) vs active surveillance patients (pts) at high risk of HCC recurrence following resection or ablation with curative intent. Further, the safety was generally manageable. Here, we additionally report PRO data from IMbrave050. Methods: IMbrave050 (NCT04102098) enrolled pts ablation. Pts were randomized to Arm A (atezo bev) B...
To compare the accuracy of multiple diagnostic tests in a single study, three designs are commonly used (i) test comparison design; (ii) randomized design, and (iii) non-comparative design. Existing meta-analysis methods (MA-DT) have been focused on evaluating performance by comparing it with reference test. The increasing number available instruments for disease condition different study being generated need to develop efficient flexible framework combine all simultaneous inference. In this...
Abstract Purpose: In the randomized phase II LOTUS trial, combining ipatasertib with first-line paclitaxel for triple-negative breast cancer (TNBC) improved progression-free survival (PFS), particularly in patients PIK3CA/AKT1/PTEN-altered tumors. We aimed to validate these findings a biomarker-selected TNBC population. Patients and Methods: Cohort A of double-blind placebo-controlled III IPATunity130 taxane-eligible measurable advanced no prior chemotherapy disease were 2:1 (400 mg, days...
Abstract ROR1, a receptor tyrosine kinase-like orphan receptor, is key mediator of non-canonical Wnt signaling and plays critical role in cancer progression. ROR1 selectively highly expressed various solid tumors hematological malignancies while absent normal adult tissues, making it promising target for therapy. Despite this potential, the lack effective tools has hindered sensitive detection patient tumor samples by IHC. To address this, we have developed recombinant rabbit monoclonal...
Abstract Introduction The API AutosomalDominant AD (ADAD) Colombia Trial is a placebo‐controlled clinical trial of crenezumab in 252 cognitively unimpaired 30 to 60‐year‐old Presenilin 1 (PSEN1) E280A kindred members, including mutation carriers randomized active treatment or placebo and non‐carriers who receive placebo. Methods Of the enrolled, we present data on total 242 matched by age range, excluding 10 participants protect participant confidentiality, genetic status, integrity. Results...
In studies evaluating the accuracy of diagnostic tests, three designs are commonly used, crossover, randomized, and noncomparative. Existing methods for meta-analysis tests mainly consider simple cases in which reference test all or none can be considered a gold standard test, use either randomized noncomparative design. The proliferation instruments diversity study create need more general to combine that include do not various designs. This article extends Bayesian hierarchical summary...
Background: Composite outcomes, which combine multiple types of clinical events into a single outcome, are common in trials. The usual analysis considers the time to first occurrence any event composite. major criticisms such an approach (1) this implicitly treats outcomes as if they were equal importance, but often vary terms relevance and severity, (2) study participants experience more than one type event, (3) less severe occur before ones, disregards information beyond that event....
10000 Background: Entrectinib previously yielded durable responses in children with NTRK or ROS1 fusion-positive extracranial solid primary CNS tumors STARTRK-NG (NCT02650401). We present updated data from STARTRK-NG, TAPISTRY (NCT04589845) and STARTRK-2 (NCT02568267): pediatric patients these trials were combined to enable an integrated efficacy safety analysis on a larger cohort than previously. Methods: Eligible TRK inhibitor naïve aged < 18 years, had locally advanced metastatic...
The combination of transarterial chemoembolization, molecular targeted therapy, and immunotherapy (triple therapy) has shown promising outcomes in the treatment unresectable hepatocellular carcinoma (HCC). This study aimed to build a prognostic model identify patients who could benefit from triple therapy.
In observational studies, misclassification of exposure is ubiquitous and can substantially bias the estimated association between an outcome exposure. Although in a single study has been well studied, few papers have considered it meta‐analysis. Meta‐analyses studies provide important evidence for health policy decisions, especially when large randomized controlled trials are unethical or unavailable. It imperative to account properly meta‐analysis obtain valid point interval estimates....